sts1 Antibody

What is Sts1 and what are its key functions in cellular signaling?

Sts1 (also known as UBASH3B) is a ubiquitin-associated and SH3 domain-containing protein B that plays critical roles in multiple cellular processes. This 72.7 kDa protein (649 amino acids in humans) functions primarily as a negative regulator of receptor tyrosine kinase signaling pathways . Its key functions include:

• Interference with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases

• Promotion of activated target receptor accumulation (including T-cell receptors and EGFR) on the cell surface

• Exhibition of tyrosine phosphatase activity toward several substrates including EGFR, FAK, SYK, and ZAP70

• Down-regulation of proteins that are dually modified by both protein tyrosine phosphorylation and ubiquitination

• Targeting of proteasomes to the nucleus, which facilitates the degradation of nuclear proteins

Sts1's phosphatase activity specifically targets the tyrosine kinase Zap-70, contributing to its role as a suppressor of T cell receptor signaling pathways .

What are the primary research applications for Sts1 antibodies?

Sts1 antibodies serve multiple research purposes across immunology, cell signaling, and cancer research fields. Based on current literature, primary applications include:

• Western Blot (WB) analysis for detecting and quantifying Sts1 protein expression in cell/tissue lysates

• Immunocytochemistry/Immunofluorescence (ICC/IF) for visualizing subcellular localization of Sts1 in fixed cells

• Flow cytometry (intracellular) for analyzing Sts1 expression in specific cell populations

• Immunoprecipitation studies to investigate Sts1 protein interactions with binding partners

• Analysis of T cell signaling pathway regulation mechanisms

• Investigation of proteasome localization and nuclear protein degradation processes

How is Sts1 involved in T cell receptor signaling regulation?

Sts1 functions as a critical negative regulator of T cell receptor (TCR) signaling through its phosphatase activity. According to multiple studies, Sts1:

• Directly targets the tyrosine kinase Zap-70, a key mediator of TCR signaling, through its phosphatase activity

• Contains a phosphoglycerate mutase/acid phosphatase (PGM/AcP) family domain that is essential for its phosphatase function

• Requires conserved active site residues (Arg-379, His-380, Arg-462, and His-565) for its catalytic activity

• Forms part of a regulatory mechanism that ensures appropriate T cell responses to antigenic stimuli

• When deleted (along with Sts-2) in knockout models, results in enhanced T cell responses to TCR stimulation

The phosphatase activity of Sts1 provides a crucial checkpoint in TCR signaling cascades, preventing inappropriate immune activation by dephosphorylating key signaling intermediates.

What are the optimal conditions for using Sts1 antibodies in Western blotting?

For optimal Western blot results with Sts1 antibodies, researchers should consider the following protocol parameters:

• Dilution ratio: 1/2000 dilution of anti-Sts1 rabbit recombinant monoclonal antibody (e.g., EPR16980) typically provides optimal results

• Blocking conditions: 5% non-fat dry milk (NFDM) in TBST has been validated for blocking membranes

• Sample types: Human cell lines like HepG2 (hepatocellular carcinoma) and Jurkat (T lymphocyte) lysates have been confirmed to yield reliable detection of Sts1

• Expected band size: ~72.7 kDa for human Sts1

• Controls: Include positive control lysates from cells known to express Sts1 (e.g., Jurkat cells for immune cell research)

• Detection method: Secondary antibodies conjugated to fluorophores or HRP can be used depending on your imaging system

A typical Western blotting protocol includes sample preparation in reducing conditions, SDS-PAGE separation, transfer to a PVDF or nitrocellulose membrane, blocking with 5% NFDM/TBST, primary antibody incubation (4°C overnight), washing, secondary antibody incubation, washing, and detection.

How can Sts1 antibodies be utilized effectively in immunofluorescence studies?

For successful immunofluorescence detection of Sts1, consider these methodological guidelines:

• Fixation methods: 4% paraformaldehyde (10-15 minutes at room temperature) preserves Sts1 antigenicity while maintaining cellular architecture

• Permeabilization: 0.1-0.2% Triton X-100 in PBS (5-10 minutes) enables antibody access to intracellular Sts1

• Blocking solution: 1-5% BSA or 5-10% normal serum from the secondary antibody host species

• Primary antibody dilution: Start with 1:100-1:200 dilutions and optimize based on signal-to-noise ratio

• Incubation conditions: Overnight at 4°C typically yields specific staining

• Nuclear counterstain: DAPI or Hoechst can be used to visualize nuclei, especially important since Sts1 has both cytoplasmic and nuclear localization

• Mounting medium: Use anti-fade mounting medium to preserve fluorescence

• Controls: Include negative controls (secondary antibody only) and positive controls (cell types known to express Sts1)

Due to Sts1's dual localization in both cytoplasm and nucleus, co-staining with compartment-specific markers can provide valuable insights into its functional distribution under different experimental conditions .

What considerations are important when selecting an Sts1 antibody for specific research applications?

Selection of the appropriate Sts1 antibody is critical for experimental success. Consider these criteria during antibody selection:

• Target specificity: Verify the antibody specificity for Sts1 versus its homolog Sts2, which shares functional domains

• Recognized epitope: Antibodies targeting different domains (UBA, SH3, or PGM) may yield different results depending on protein interactions or conformational states

• Validated applications: Ensure the antibody has been validated for your specific application (WB, ICC/IF, Flow Cytometry)

• Host species: Consider compatibility with other antibodies for co-staining experiments

• Monoclonal vs. polyclonal: Monoclonal antibodies offer higher specificity but may be sensitive to epitope modifications; polyclonal antibodies provide robust detection but potentially higher background

• Species reactivity: Human Sts1 antibodies may not cross-react with mouse or other species due to sequence variations

• Citations: Antibodies with published research citations provide higher confidence in their performance

For multi-color flow cytometry or immunofluorescence, consider antibody conjugates or detection systems that minimize spectral overlap with other fluorophores in your experimental design.

How can mutations in Sts1's phosphatase domain be analyzed to understand its functional mechanisms?

Analysis of Sts1 phosphatase domain mutations provides crucial insights into its structure-function relationships. A methodological approach includes:

• Identification of critical catalytic residues: Based on structural analysis, key residues in the phosphoglycerate mutase/acid phosphatase (PGM/AcP) domain include Arg-379, His-380, Arg-462, and His-565

• Site-directed mutagenesis: Generate individual alanine substitutions of these residues using PCR-based techniques

• In vitro phosphatase assays: Assess enzymatic activity of wild-type versus mutant proteins using synthetic phosphopeptides or specific protein substrates like phosphorylated Zap-70

• Functional cellular assays: Express wild-type and mutant Sts1 in appropriate cell lines (e.g., Jurkat T cells) to measure effects on TCR signaling

• Complementation studies: Introduce wild-type or mutant Sts1 into Sts1/2-deficient T cells to assess rescue of phenotypes

• Protein interaction analysis: Determine if mutations affect binding to substrates or other interacting proteins

• Subcellular localization: Use immunofluorescence to determine if mutations alter the nuclear/cytoplasmic distribution of Sts1

Research has demonstrated that point mutations in the catalytic site residues significantly impair both in vitro phosphatase activity and the ability of Sts1 to regulate TCR signaling in T cells, confirming the mechanistic importance of this domain .

What is the relationship between Sts1 and proteasome targeting to the nucleus, and how can this be investigated?

The role of Sts1 in nuclear proteasome targeting represents an important research area that can be investigated through these approaches:

• Genetic manipulation: Utilize specific sts1 mutants or overexpression systems to modulate Sts1 levels and activity

• Proteasome localization analysis: Employ immunofluorescence, cell fractionation, and Western blotting to track proteasome distribution between cytoplasm and nucleus

• Interaction studies: Investigate Sts1 binding to nuclear import factors like Srp1, which recognizes nuclear localization signals (NLS)

• Domain mapping: Create deletion constructs lacking the NLS in Sts1 to determine effects on nuclear proteasome localization

• Functional assays: Measure degradation of nuclear protein substrates in the presence of wild-type versus mutant Sts1

• Suppression analysis: Examine how Sts1 suppresses proteolytic and localization defects in rad23Δ rpn10Δ double mutants

Research has shown that specific sts1 mutants exhibit reduced nuclear proteasomes at non-permissive temperatures, while high expression of Sts1 increases nuclear proteasome levels. The mechanism involves Sts1 interaction with Srp1, as deletion of the NLS in Sts1 prevents this interaction and causes proteasome mislocalization .

How do Sts1 inhibitors like baicalein affect hematopoietic stem/progenitor cell function, and what techniques can assess this relationship?

The effects of Sts1 inhibitors such as baicalein (BC) on hematopoietic stem/progenitor cells (HSPCs) can be investigated using these methodological approaches:

• In vitro phosphatase assays: Determine the inhibitory potential of baicalein against recombinant STS1 and STS2 phosphatase domains

• Dose-response analysis: Establish EC50 values for baicalein inhibition of STS1/STS2 activity

• Molecular docking: Use computational approaches to model baicalein binding to the STS1/STS2 phosphatase domains

• Signaling pathway analysis: Assess the phosphorylation status of STS1/STS2 substrates (e.g., FLT3, cKIT) after baicalein treatment

• HSPC expansion assays: Quantify the effects of baicalein on primary HSPC populations in vitro

• Colony-forming unit (CFU) assays: Measure multilineage differentiation capacity of baicalein-treated HSPCs

• In vivo administration: Administer baicalein to mice and analyze bone marrow and spleen cell populations

• Flow cytometry analysis: Quantify stem/progenitor populations (LT-HSC, ST-HSC, MPP) following treatment

Research has demonstrated that baicalein inhibits STS1 and STS2 phosphatase activities, leading to enhanced expansion of mouse LSK populations and human primary HSC populations, and improved multilineage differentiation capacity both in vitro and in vivo .

What are the common challenges when using Sts1 antibodies in research, and how can they be addressed?

Researchers commonly encounter these challenges when working with Sts1 antibodies:

• Cross-reactivity with Sts2: Due to homology between Sts1 and Sts2, antibodies may recognize both proteins. Solution: Validate antibody specificity using overexpression or knockout systems for each protein individually

• Low signal intensity: May occur due to low expression levels in certain cell types. Solution: Optimize antibody concentration, incubation time, and detection methods; consider signal amplification techniques

• High background: Can result from non-specific binding. Solution: Increase blocking time/concentration; optimize antibody dilution; include additional washing steps

• Inconsistent detection: May arise from sample preparation variability. Solution: Standardize lysis protocols, ensure consistent loading, and include appropriate controls

• Post-translational modifications affecting epitope recognition: Solution: Try antibodies targeting different regions of Sts1

• Nuclear versus cytoplasmic distribution variability: Solution: Use careful cell fractionation techniques and appropriate markers for each compartment

• Proteolytic degradation: Solution: Add protease inhibitors to all buffers during sample preparation

Including appropriate positive and negative controls in each experiment is essential for troubleshooting and validating Sts1 antibody performance.

How can researchers interpret contradictory results between Sts1 expression and functional assays?

When facing discrepancies between Sts1 expression data and functional outcomes, consider these analytical approaches:

• Activity versus expression analysis: Sts1 phosphatase activity may be regulated independently of its expression level through post-translational modifications or protein interactions

• Domain-specific functions: Different domains of Sts1 (UBA, SH3, PGM) contribute to distinct functions; analyze which function you are assessing relative to the expression data

• Context-dependent activity: The function of Sts1 depends on its interacting partners and cellular context; characterize the expression of key interactors

• Compensatory mechanisms: Sts2 may compensate for Sts1 in certain contexts; analyze both proteins simultaneously

• Technical considerations: Antibody epitopes may be masked by protein-protein interactions or modifications in functional states

• Quantitative analysis: Use quantitative approaches (e.g., quantitative Western blotting, flow cytometry) to correlate expression levels with functional outcomes

• Time-course experiments: Temporal differences between expression changes and functional effects may explain apparent contradictions

For comprehensive analysis, combine expression studies with functional assays and biochemical analyses of Sts1 phosphatase activity under your specific experimental conditions.

What experimental designs can help differentiate between the roles of Sts1 and its homolog Sts2 in T cell signaling?

Distinguishing the specific contributions of Sts1 versus Sts2 requires strategic experimental designs:

• Single and double knockout models: Compare phenotypes of Sts1-/-, Sts2-/-, and Sts1/2-/- models to identify unique and redundant functions

• Rescue experiments: Reintroduce Sts1 or Sts2 individually into double knockout cells to identify which functions each protein can restore

• Domain swap constructs: Create chimeric proteins exchanging domains between Sts1 and Sts2 to map domain-specific functions

• Substrate specificity analysis: Compare the phosphatase activities of purified Sts1 and Sts2 against potential physiological substrates in vitro

• Selective inhibition: Use inhibitors with differential potency against Sts1 versus Sts2 (if available) to dissect their roles

• Phosphoproteomics: Compare the phosphoproteomic profiles of cells lacking Sts1, Sts2, or both to identify specific substrates

• Interaction partner identification: Use co-immunoprecipitation followed by mass spectrometry to identify unique binding partners

• Expression pattern analysis: Map the tissue and cellular distribution of both proteins to identify contexts where only one is expressed

Research has demonstrated that while Sts1 and Sts2 share structural similarities, they exhibit differences in catalytic efficiency, with Sts1 showing higher phosphatase activity in many contexts, explaining why Sts1 often plays a more dominant role in T cell signaling regulation .

How might Sts1-targeted approaches be developed for immunotherapy applications?

Developing Sts1-targeted approaches for immunotherapy represents a promising frontier based on current understanding:

• Selective inhibitor development: Design small molecules that specifically target the phosphatase domain of Sts1 with minimal off-target effects

• T cell enhancement strategies: Exploit Sts1 inhibition to enhance T cell responses against cancer cells by prolonging TCR signaling

• Combination therapies: Pair Sts1 inhibitors with existing checkpoint inhibitors to potentially synergize immune activation

• Delivery systems: Develop targeted delivery methods to direct Sts1 modulators specifically to immune cells

• Predictive biomarkers: Identify patient populations likely to benefit from Sts1-targeted therapies based on expression profiles

• Regulatable systems: Create conditional systems to modulate Sts1 activity in a temporally controlled manner

• Hematopoietic stem cell applications: Utilize Sts1 inhibitors like baicalein to expand HSPCs ex vivo for transplantation applications

The dual role of Sts1 in T cell signaling and proteasome targeting suggests multiple potential therapeutic applications that warrant further investigation in preclinical models before advancing to clinical development.

What emerging technologies could enhance our understanding of Sts1's role in proteasome regulation?

Several cutting-edge technologies offer new opportunities to explore Sts1's proteasome regulatory functions:

• Live-cell imaging with fluorescently tagged proteasomes: Track real-time movement of proteasomes in the presence/absence of functional Sts1

• CRISPR-Cas9 genome editing: Generate precise mutations in endogenous Sts1 to study effects on proteasome localization and function

• Proximity labeling techniques (BioID, APEX): Map the Sts1 interactome specifically at the nuclear envelope or within the nucleus

• Single-molecule tracking: Analyze the dynamics of individual proteasome complexes and their interaction with Sts1

• Cryo-electron microscopy: Determine high-resolution structures of Sts1 in complex with proteasomes and nuclear import factors

• Optogenetics: Create light-activatable versions of Sts1 to control its activity spatiotemporally

• Degradomics: Profile the repertoire of nuclear substrates affected by alterations in Sts1-mediated proteasome targeting

• Spatial transcriptomics: Correlate Sts1 activity with region-specific changes in gene expression within the nucleus

These approaches could address fundamental questions about how Sts1 selectively targets proteasomes to the nucleus and regulates the degradation of specific nuclear proteins under different cellular conditions .

How does Sts1 function at the intersection of phosphorylation and ubiquitination pathways, and what experimental designs could elucidate this crosstalk?

Investigating Sts1's role at the nexus of phosphorylation and ubiquitination pathways requires sophisticated experimental designs:

• Dual modification proteomics: Develop enrichment strategies to isolate proteins simultaneously modified by phosphorylation and ubiquitination

• Sequential enzyme assays: Examine how prior phosphorylation affects subsequent ubiquitination of substrates, and vice versa

• Structure-function analysis: Map how the UBA and phosphatase domains of Sts1 coordinate to recognize dually modified substrates

• In vitro reconstitution systems: Reconstitute minimal systems with purified components to dissect the sequential events in substrate recognition and processing

• Time-resolved mass spectrometry: Track the dynamic changes in modification status of Sts1 substrates

• Specific substrate studies: Focus on well-characterized targets like EGFR, ZAP-70, or FAK to examine dual modification states

• Mathematical modeling: Develop computational models of how phosphorylation-ubiquitination crosstalk affects signaling dynamics

• Systems biology approaches: Map the network effects of Sts1 perturbation on global phosphorylation and ubiquitination landscapes

Understanding this regulatory intersection could provide insights into how cells integrate multiple post-translational modification systems to achieve precise control of protein function and turnover .